News Headlines Article

FDA panel’s vote on Avandia reveals mixed opinions on diabetes drug’s safety
Washington Post

Federal advisers delivered a mixed verdict Wednesday on the diabetes drug Avandia, with a significant number of experts voting to recommend that it be pulled from the market because of safety concerns but a majority urging to keep it available, perhaps with tough new restrictions and new warnings.

The highly anticipated recommendations by the Food and Drug Administration advisory panel mark a crucial development in the long debate over Avandia, which was once the world’s most popular diabetes drug but has become the focus of intense debate because of concerns that it increases the risk for heart attacks and strokes.